3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Floxuridine
2
trastuzumab deruxtecan
1
tinostamustine
1
pexidartinib
1
pembrolizumab
1
motexafin lutetium
1
Trabectedin
1
Specimen Handling
1
Psychiatric Rehabilitation
1
Oxaliplatin
1
Octreotide
1
OSI 930
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Imatinib Mesylate
1
Gemcitabine
1
Fentanyl
1
Early Intervention, Educational
1
Counseling
1
Cisplatin
1
Carboplatin
1
CTLA-4 Antigen
1
7-hydroxystaurosporine
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
tinostamustine
×
Gynecologic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts